118 related articles for article (PubMed ID: 21378364)
1. Expression of the vascular endothelial growth factor (VEGF) gene in epithelial ovarian cancer: an approach to anti-VEGF therapy.
Hata K; Watanabe Y; Nakai H; Hata T; Hoshiai H
Anticancer Res; 2011 Feb; 31(2):731-7. PubMed ID: 21378364
[TBL] [Abstract][Full Text] [Related]
2. Expression of the angopoietin-1, angopoietin-2, Tie2, and vascular endothelial growth factor gene in epithelial ovarian cancer.
Hata K; Nakayama K; Fujiwaki R; Katabuchi H; Okamura H; Miyazaki K
Gynecol Oncol; 2004 Apr; 93(1):215-22. PubMed ID: 15047239
[TBL] [Abstract][Full Text] [Related]
3. RhoC expression level is correlated with the clinicopathological characteristics of ovarian cancer and the expression levels of ROCK-I, VEGF, and MMP9.
Zhao Y; Zong ZH; Xu HM
Gynecol Oncol; 2010 Mar; 116(3):563-71. PubMed ID: 20022093
[TBL] [Abstract][Full Text] [Related]
4. [Expression and clinical significance of endostatin and vascular endothelial growth factor in ovarian carcinoma].
Shi HR; Song WJ; Chen ZM; Wu QH
Ai Zheng; 2005 Sep; 24(9):1127-31. PubMed ID: 16159439
[TBL] [Abstract][Full Text] [Related]
5. Vascular endothelial growth factor and interleukin-8 are associated with poor prognosis in epithelial ovarian cancer patients.
Kassim SK; El-Salahy EM; Fayed ST; Helal SA; Helal T; Azzam Eel-D; Khalifa A
Clin Biochem; 2004 May; 37(5):363-9. PubMed ID: 15087251
[TBL] [Abstract][Full Text] [Related]
6. Expression of metastin and a G-protein-coupled receptor (AXOR12) in epithelial ovarian cancer.
Hata K; Dhar DK; Watanabe Y; Nakai H; Hoshiai H
Eur J Cancer; 2007 Jun; 43(9):1452-9. PubMed ID: 17442564
[TBL] [Abstract][Full Text] [Related]
7. Prognostic significance of vascular endothelial growth factor expression in human ovarian carcinoma.
Shen GH; Ghazizadeh M; Kawanami O; Shimizu H; Jin E; Araki T; Sugisaki Y
Br J Cancer; 2000 Jul; 83(2):196-203. PubMed ID: 10901370
[TBL] [Abstract][Full Text] [Related]
8. Gene expression of vascular endothelial growth factor A, thymidylate synthase, and tissue inhibitor of metalloproteinase 3 in prediction of response to bevacizumab treatment in colorectal cancer patients.
Watanabe T; Kobunai T; Yamamoto Y; Matsuda K; Ishihara S; Nozawa K; Iinuma H; Ikeuchi H
Dis Colon Rectum; 2011 Aug; 54(8):1026-35. PubMed ID: 21730794
[TBL] [Abstract][Full Text] [Related]
9. Serum vascular endothelial growth factor in epithelial ovarian neoplasms: correlation with patient survival.
Chen CA; Cheng WF; Lee CN; Chen TM; Kung CC; Hsieh FJ; Hsieh CY
Gynecol Oncol; 1999 Aug; 74(2):235-40. PubMed ID: 10419737
[TBL] [Abstract][Full Text] [Related]
10. The predictive value of serum VEGF in multiresistant ovarian cancer patients treated with bevacizumab.
Smerdel MP; Steffensen KD; Waldstrøm M; Brandslund I; Jakobsen A
Gynecol Oncol; 2010 Aug; 118(2):167-71. PubMed ID: 20471067
[TBL] [Abstract][Full Text] [Related]
11. Nerve growth factor and its high-affinity receptor trkA participate in the control of vascular endothelial growth factor expression in epithelial ovarian cancer.
Campos X; Muñoz Y; Selman A; Yazigi R; Moyano L; Weinstein-Oppenheimer C; Lara HE; Romero C
Gynecol Oncol; 2007 Jan; 104(1):168-75. PubMed ID: 16935322
[TBL] [Abstract][Full Text] [Related]
12. Vascular endothelial growth factor expression in ovarian cancer: a model for targeted use of novel therapies?
Duncan TJ; Al-Attar A; Rolland P; Scott IV; Deen S; Liu DT; Spendlove I; Durrant LG
Clin Cancer Res; 2008 May; 14(10):3030-5. PubMed ID: 18483368
[TBL] [Abstract][Full Text] [Related]
13. Association of metastin/a G-protein-coupled receptor signaling and Down syndrome critical region 1 in epithelial ovarian cancer.
Hata K; Watanabe Y; Nakai H; Minami T; Ohsaki H; Hirakawa E; Hoshiai H
Anticancer Res; 2009 Feb; 29(2):617-23. PubMed ID: 19331211
[TBL] [Abstract][Full Text] [Related]
14. [Prognostic value of microvessel density and angiogenesis-related molecules in epithelial ovarian cancer].
Tan XJ; Lang JH; Lou WZ; Shen K; Xu XY
Zhonghua Zhong Liu Za Zhi; 2008 Apr; 30(4):274-8. PubMed ID: 18788631
[TBL] [Abstract][Full Text] [Related]
15. Association of VEGF-A splice variant mRNA expression with outcome in bevacizumab-treated patients with metastatic breast cancer.
Pentheroudakis G; Kotoula V; Kouvatseas G; Charalambous E; Dionysopoulos D; Zagouri F; Koutras A; Papazisis K; Pectasides D; Samantas E; Dimopoulos MA; Papandreou CN; Fountzilas G
Clin Breast Cancer; 2014 Oct; 14(5):330-8. PubMed ID: 24703319
[TBL] [Abstract][Full Text] [Related]
16. Vascular endothelial growth factor messenger RNA expression level is preserved in liver metastases compared with corresponding primary colorectal cancer.
Kuramochi H; Hayashi K; Uchida K; Miyakura S; Shimizu D; Vallböhmer D; Park S; Danenberg KD; Takasaki K; Danenberg PV
Clin Cancer Res; 2006 Jan; 12(1):29-33. PubMed ID: 16397020
[TBL] [Abstract][Full Text] [Related]
17. [Study of the correlation between HER-2 gene and lymphangiogenesis and their prognostic significance in human breast cancer].
Zhang GH; Yang WT; Zhou XY; Zeng Y; Lu HF; Shi DR
Zhonghua Yi Xue Za Zhi; 2007 Jan; 87(3):155-60. PubMed ID: 17425844
[TBL] [Abstract][Full Text] [Related]
18. Gene expression profiles of epidermal growth factor receptor, vascular endothelial growth factor and hypoxia-inducible factor-1 with special reference to local responsiveness to neoadjuvant chemoradiotherapy and disease recurrence after rectal cancer surgery.
Toiyama Y; Inoue Y; Saigusa S; Okugawa Y; Yokoe T; Tanaka K; Miki C; Kusunoki M
Clin Oncol (R Coll Radiol); 2010 May; 22(4):272-80. PubMed ID: 20117921
[TBL] [Abstract][Full Text] [Related]
19. The relationship between proangiogenic gene expression levels in prostate cancer and their prognostic value for clinical outcomes.
Mori R; Dorff TB; Xiong S; Tarabolous CJ; Ye W; Groshen S; Danenberg KD; Danenberg PV; Pinski JK
Prostate; 2010 Nov; 70(15):1692-700. PubMed ID: 20564320
[TBL] [Abstract][Full Text] [Related]
20. Relative expression levels of Th1 and Th2 cytokine mRNA are independent prognostic factors in patients with ovarian cancer.
Kusuda T; Shigemasa K; Arihiro K; Fujii T; Nagai N; Ohama K
Oncol Rep; 2005 Jun; 13(6):1153-8. PubMed ID: 15870936
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
